PCN119 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI